Comparison of the usefulness of plasma levels of oxidatively modified forms of albumin in estimating kidney dysfunction in diabetic patients

Clinical and Investigative Medicine

Volumn 33, Issue 2, 2010, Pages

  Piwowar, Agnieszka ^a   Knapik Kordecka, Maria ^a   Warwas, Maria ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CREATININE; SERUM ALBUMIN;

AGED; ALBUMINURIA; ARTICLE; BLOOD; COMPARATIVE STUDY; DIABETIC NEPHROPATHY; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; URINE; COMPLICATION; DIABETIC NEPHROPATHIES;

AGED; ALBUMINURIA; BIOLOGICAL MARKERS; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; ROC CURVE; SENSITIVITY AND SPECIFICITY; SERUM ALBUMIN;

EID: 77951791815     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Bar-Or D, Lau E, Winkler J. A novel assay for cobaltalbumin binding and its potential as a marker of myocardial ischemia - a preliminary report. J Emerg Med 2000;19:311-5.
2. Martin-Gallan P, Carrascosa A, Gussinye M, Dominguez C. Biomarkers of diabetes associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Rad Biol Med 2003;34:1563-74. (Pubitemid 36638716)
3. Cakatay U. Protein oxidation parameters in type 2 diabetic patients with good and poor glycaemic control. Diabetes Metab 2005;31:551-7. (Pubitemid 43001172)
4. Piwowar A, Knapik-Kordecka M, Warwas M. AOPP and its relations with selected markers of oxidative/antioxidative system in type 2 diabetes mellitus. Diabetes Res Clin Pract 2007;77:188-92. (Pubitemid 46670416)
5. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304-13. (Pubitemid 26166404)
6. Mera K, Anraku M, Kitamura K, Nakajou K, Maruyama T, Otagiri M. The structure and function of oxidized albumin in hemodialysis patients: Its role in elevated oxidative stress via neutrophil burst. Biochem Biophys Res Commun 2005;334:1322-8. (Pubitemid 41074719)
7. Apple FS, Quist HE. Release characteristics of cardiac biomarkers and ischemia-modified albumin as measured by the albumin cobalt-binding test after a marathon race. Clin Chem 2002;48:1097-100.
8. Collinson PO, Gaze DC. Ischemia-modified albumin: clinical utility and pitfalls in measurement. J Clin Pathol 2008;61:1025-8.
9. Piwowar A, Knapik-Kordecka M, Warwas M. Ischemia-modified albumin level in type 2 diabetes mellitus - Preliminary report. Dis Markers 2008;24:311-7.
10. Roy D, Quiles J, Sharma R, et al. Ischemia-modified albumin concentrations in patients with peripheral vascular disease and exercise-induced skeletal muscle ischemia. Clin Chem 2004;50:1656-60. (Pubitemid 39121235)
11. Borderie D, Allanore Y, Meune C, Devaux JY, Ekindjian OG, Kahan A. High ischemia-modified albumin concentration reflects oxidative stress but not myocardial involvement in systemic sclerosis. Clin Chem 2004;50:2190-3. (Pubitemid 39425871)
12. Skvarilova M, Bulava A, Stejskal D, Adamovská S, Bartek J. Increased level of advanced oxidation products (AOPP) as a marker of oxidative stress in patients with acute coronary syndrome. Biomed Papers 2005;149:83-7.
13. Baskol G, Demir H, Baskol M, et al. Investigation of protein oxidation and lipid peroxidation in patients with rheumatoid arthritis. Cell Biochem Funct 2006;24:307-11. (Pubitemid 44065233)
14. Can M, Demirtas S, Polat O, Yildiz A. Evaluation of effects of ischaemia on the albumin cobalt binding (ACB) assay in patients exposed to trauma. Emerg Med J 2006;23:537-9. (Pubitemid 44295259)
15. Turedi S, Gunduz A, Mentese A, et al. Value of ischemia-modified albumin in the diagnosis of pulmonary embolism. Am J Emerg Med 2007;25:770-3. (Pubitemid 47385040)
16. Knapik-Kordecka M, Piwowar A, Warwas M. Oxidative-antioxidative balance disturbance and risk factors as well as vascular complications in patients with diabetes type 2. Wiad Lek 2007;60:329-34 [Polish text].
17. Piwowar A, Knapik-Kordecka M, Szczecińska J, Warwas M. Plasma glycooxidation protein products in type 2 diabetic patients with nephropathy. Diabetes Metab Res Rev 2008;24:549-53.
18. Incerti J, Zelmanovitz T, Camargo JL, Gross JL, de Azevedo MJ. Evaluation of tests for microalbuminuria screening in patients with diabetes. Nephrol Dial Transplant 2005;20:2402-7. (Pubitemid 41548863)
19. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 2008;4:444-52.
20. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005;28:64-76.
21. Jafar TH, Chaturvedi N, Hatcher J, Levey AS. Use of albumin creatinine ratio and urine albumin concentration as a screening test for albuminuria in an Indo- Asian population. Nephrol Dial Transplant 2007;22:2194-200. (Pubitemid 47244696)
22. de Fine Olivarius N, Andreasen AH, Vestbo E, Holstein-Rathlou NH, Jorgensen LG, Mogensen CE. Urinary creatinine concentration is inversely related to glycaemic control and the presence of some diabetic complications in patients with newly diagnosed Type 2 diabetes. J Diabetes Complications 2006;20:45-50. (Pubitemid 43028413)
23. Schosinsky KH, Vargas M, Esquinet AJ, Chavaria A. Simple spectrometric determination of urinary albumin by dye-binding with of bromophenol blue. Clin Chim Acta 1987;33:223-6. (Pubitemid 17161122)
24. Bewick V, Cheek L, Ball J. Statistics review 13: receiver operating characteristic curves. Crit Care 2004;8:508-12. (Pubitemid 40073688)
25. Dave GS, Kalia K. Hyperglycemia induced oxidative stress in type-1 and type-2 diabetic patients with and without nephropathy. Cell Mol Biol 2007;53:68-78. (Pubitemid 350164307)
26. Aslan M, Sabuncu T, Kocyigit A, Celik H, Selek S. Relationship between total oxidant status and severity of diabetic nephropathy in type 2 diabetic patients. Nutr Metab Cardiovasc Dis 2007;17:734-40. (Pubitemid 350088438)
27. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease; effects on the cardiovascular system. Circulation 2007;116:85-97. (Pubitemid 47016250)
28. Bailie GR, Ublig K, Levey AS. Clinical practice guidelines in nephrology: evaluation, classification, and stratification of chronic kidney disease. Pharmacotherapy 2005;25:491-502. (Pubitemid 40471492)
29. Kalousová M, Zima T, Tesar V, Dusilová-Sulková S, Skrha J. Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat Res 2005;579:37-46.
30. Kaneda H, Taguchi J, Ogasawara K, Aizawa T, Ohno M. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis 2002;162:221-5. (Pubitemid 34327362)
31. Sharma R, Gaze DC, Pellerin D, et al. Evaluation of ischaemia-modified albumin as a marker of myocardial ischaemia in end-stage renal disease. Clin Sci 2007;113:25-32. (Pubitemid 47066022)
32. Krzystek-Korpacka M, Neubauer K, Berdowska I, et al. Boehm Enhanced formation of advanced oxidation protein products in IBD. Inflamm Bowel Dis 2008;14:794-802. (Pubitemid 351898064)
33. Mojiminiyi OA, Abdella N. Evaluation of cystatin C and beta-2 microglobulin as markers of renal function in patients with type 2 diabetes mellitus. J Diabetes Complications 2003;17:160-8. (Pubitemid 36547818)
34. Uslu S, Efe B, Alataş. O, et al. Serum cystatin C and urinary enzymes as screening markers of renal dysfunction in diabetic patients. J Nephrol 2005;18:559-67. (Pubitemid 41824476)
35. Pucci L, Triscornia S, Lucchesi D, et al. Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin Chem. 2007;53:480-8. (Pubitemid 46447945)